Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2011

View Archived Issues

New epigenetic therapy for aggressive leukemia shows promise in vivo

Novel target and agents explored for treating hypertension

Presentations provide further phase II data on lesinurad in gout

Abatacept shows efficacy in subgroup of patients with lupus nephritis

New beta-secretase 1 inhibitors disclosed by Array BioPharma and Genentech

GLCCI1 gene variants linked to response to inhaled glucocorticoid asthma therapy

Novel kinesin-like protein KIF11 inhibitors presented

Scientists present new MAP kinase p38 inhibitors

Dainippon Sumitomo Pharma reviews activities of second quarter of fiscal year 2011

University of North Carolina team patents novel anisamide-oligonucleotide conjugates

LivTech and Yakult Honsha enter option agreement for LIV-2008 anticancer program

Gilead Sciences and the Cardiovascular Research Foundation start new ranolazine trial

Novel vaccines for human cytomegalovirus infection prepared in Germany

Taisho Pharmaceutical recaps events of second quarter of fiscal year 2011

Corimmun discloses new fusion proteins for cardiovascular diseases

NeurogesX reports encouraging results on NGX-1998 in postherpetic neuralgia

EC grants marketing authorization to orphan drug for adrenal insufficiency in adults

Lilly and Amylin reach agreement to terminate diabetes alliance

Ablynx and Merck Serono enter new Nanobodies collaboration

Salix Pharmaceuticals to acquire Oceana Therapeutics

FDA approves Erbitux for new indication

FDA accepts NDA for vismodegib

Gen-Probe files notice relating to FDA review of Progensa PCA3 assay

Opexa Therapeutics' lead product receives FDA fast track status

BARDA awards contract to RxBio to develop radiomitigant countermeasure drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...